IBSA, kendi patentli diklofenak epolamin (EP) tuzunu baz alan eksiksiz bir NSAID ürün dizisi geliþtirmiþtir. EP diklofenak, hem sulu, hem de lipid içeren kompartýmanlarda yüksek derecede çözünürlük göstermesi nedeniyle transdermal uygulama için mükemmel bir moleküldür.

Mevcut lisanslama fýrsatlarý aþaðýda verilmiþtir.

Description
Adhesive plasters containing 180 mg of diclofenac epolamine. The active substance in dissolved in 14 grams of hydrogel ensuring the sustained release for 12-24 hours.

Indication
For the symptomatic relief of rheumatic pain, lumbago and muscular aches, pains and swellings such as strains, sprains and sports injuries.

Status
Approved and marketed in the majority of the EU countries (MRP) as well as in many non-EU countries. According to the country, the product may be approved as ethical or as OTC.

Claims
Effective transdermal delivery without systemic side effects. Clean and practical, avoids the need for occlusive bandages. Very first available NSAID plaster, it is market leader in many countries.

Countries available for licensing
Available on semi-exclusive basis for UK.

For details see Page Extensions

For information please contact: